Home/ Stocks/ IMMX

Immix Biopharma, Inc. Common Stock

IMMX XNAS

$9.75 +0.02 (+0.21%) ▲ 15-min delayed

Open

$9.37

High

$10.08

Low

$9.18

Volume

661.3K

Market Cap

$530.51M

About Immix Biopharma, Inc. Common Stock

Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 21 Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$0	$-29,438,613	$-0.89
FY 2025	$0	$-29,438,613	$-0.89
Q3 2025	$0	$-7,585,692	$-0.24
Q2 2025	$0	$-6,622,563	$-0.22

Earnings & Analyst Ratings

Next Earnings: Thu, Aug 6, 2026

Calendar →

Related Market News

No specific coverage for IMMX yet. Check out our latest market news or earnings calendar.

Get IMMX Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Immix Biopharma, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.